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In vivo delivery of VeGf RnA and 
protein to increase osteogenesis 
and intraosseous angiogenesis
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Lalitha thiagarajan4, James E. Dixon4, Gianluca tozzi3 & Richard o. c. Oreffo1
Deficient bone vasculature is a key component in pathological conditions ranging from developmental 
skeletal abnormalities to impaired bone repair. Vascularisation is dependent upon vascular endothelial 
growth factor (VEGF), which drives both angiogenesis and osteogenesis. The aim of this study was 
to examine the efficacy of blood vessel and bone formation following transfection with VEGF RnA or 
delivery of recombinant human VeGf165 protein (rhVeGf165) across in vitro and in vivo model systems. to 
quantify blood vessels within bone, an innovative approach was developed using high-resolution X-ray 
computed tomography (XCT) to generate quantifiable three-dimensional reconstructions. Application 
of rhVeGf165 enhanced osteogenesis, as evidenced by increased human osteoblast-like MG-63 
cell proliferation in vitro and calvarial bone thickness following in vivo administration. In contrast, 
transfection with VEGF RNA triggered angiogenic effects by promoting VEGF protein secretion from 
MG-63VEGF165 cells in vitro, which resulted in significantly increased angiogenesis in the chorioallantoic 
(cAM) assay in ovo. Furthermore, direct transfection of bone with VEGF RnA in vivo increased 
intraosseous vascular branching. this study demonstrates the importance of continuous supply as 
opposed to a single high dose of VEGF on angiogenesis and osteogenesis and, illustrates the potential 
of XCT in delineating in 3D, blood vessel connectivity in bone.
The temporal and spatial coordination of vascularisation within bone is pivotal for skeletal development includ-
ing bone formation, maintenance and repair1. Endochondral ossification is contingent on the arrival of blood 
capillaries from the periosteal bud, while, intramembranous ossification is associated with both intussusceptive 
and sprouting forms of angiogenesis2. In bone, the process of angiogenesis is coupled to osteogenesis as new blood 
vessels form in the wake of bone resorption by osteoclasts and the subsequent chemoattractant recruitment of 
osteoblast precursors to enable endochondral bone formation3–6. Vascular endothelial growth factor (VEGF) was 
first shown over two decades ago to be the key factor coupling osteogenesis and angiogenesis as inactivation of 
VEGF concomitantly subdued blood vessel invasion and bone formation7,8. VEGF receptors including VEGFR1 
(Flt1), VEGFR2 (Kdr), and VEGFR3 (Flt-4) are expressed by both blood vessel forming endothelial cells9 and 
bone forming osteoblasts10,11. In vascular endothelial cells, VEGFR2 is the main signalling VEGF receptor9, while 
the co-receptors neuropilin-1 and 2 influence endothelial cell survival, adhesion, and migration12,13. Blood vessel 
formation is dependent upon a complex signalling axis that includes hypoxia inducible factor (HIF)-1 (consisting 
of HIF-1α and HIF-1β subunits), which drives expression of VEGF that in turn acts upon VEGF receptors14. In 
osteoblasts, VEGFR1-3, neuropillin-1 and -2 are required for stimulation of osteoblast chemotaxis15, regulation 
of osteoblast development10,11, and of bone remodelling10. In addition to responding to VEGF, osteoblasts are 
known to be a predominant source of VEGF in bone and release VEGF in response to a range of factors including 
hypoxia and mechanical strain1,8.
Given the central role of skeletal blood vessels in bone formation and maintenance, it is unsurprising that 
a lack of bone vascularisation has been identified as a contributory factor in a number of bone pathologies. 
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Avascular necrosis of the femoral head has several causes including steroid treatments or alcohol abuse, which 
reduce the availability of endothelial progenitor cells and result in decreased angiogenesis within bone16. Diabetes 
patients suffer from impaired bone formation and fracture healing17, which may be a consequence of diabetes, 
related cardiovascular disease, which restricts blood supply to the bone18. Angiogenesis is pivotal in bone repair 
where one of the first responses to blunt trauma requires the formation of a hematoma around the fracture site 
accompanied by a triggering of new blood vessel formation19. A failure of angiogenesis around the injury site can 
result in bone non-union, a serious clinical complication, present in up to 9% of fracture cases20. Current treat-
ments are limited and often require invasive surgery, with long recovery times and can be dependent upon the 
available vasculature within bone grafts21–23. As these pathologies and morbidities are associated with a lack of an 
adequate functional bone vasculature, a suitable approach for treatment necessitates methods of controlling and 
enhancing angiogenesis in bone.
There are several isoforms of VEGF-A of which VEGF164/165 is the most widely studied in bone given the 
established requirement of VEGF164/165 for angiogenesis and bone formation. Maes and co-workers showed mice 
expressing VEGF120 alone, have impaired bone growth with reduced bone vascularisation and decreased expres-
sion of osteoblastic genes24. In contrast, mice expressing only VEGF188 exhibit dwarfism associated with a lack 
of vascularisation around the epiphysis and impaired cartilage development. Interestingly, the skeletons of mice 
expressing only VEGF164 exhibit normal bone structure and mineralisation demonstrating the importance of this 
isoform25. A raft of studies have confirmed osteoblast specific VEGF expression is particularly important in bone 
formation and repair. Deletion in osteoblasts of the von Hippel–Lindau gene (Vhl), which increases HIF-1α and 
subsequent VEGF expression, has been associated with increased angiogenesis and volume of long bones26. In 
craniofacial bones, deletion of Vegfa reduces osteoblast commitment27, while, VEGF derived from osteoprogeni-
tor cells is required for intramembranous ossification independently of vasculogenesis28. In an osteoblast specific 
Vegfa knockout mouse model, the absence of osteoblast-derived VEGF was linked to decreased intramembra-
nous bone formation, decreased angiogenesis and a reduction in callus remodelling as assessed using a tibial bone 
drill defect model29.
Given the importance of localised VEGF release in directing the formation of new bone and blood vessels, the 
current study set out to enhance the innate capacity of bone cell populations to generate VEGF and to quantify 
the changes in osteogenesis and angiogenesis within bone compared with administration of recombinant human 
VEGF165 protein (rhVEGF165). The effects of rhVEGF165 were compared with that of VEGF165 RNA transfection 
upon angiogenesis in ovo and in both bone formation and intraosseous vascularisation in vivo analyzed by XCT.
Results
Contrasting effects of VEGF165 RnA transfection and rhVeGf165 protein in vitro. Transfection 
with GFP RNA engendered the production of GFP protein, visible under fluorescent microscopy in a dose 
dependent manner (Fig. 1a–d). Transfection with 0.1 and 0.5 µg per well was insufficient to generate detectable 
GFP expression (Fig. 1a,b, respectively). Transfection with 1 µg and 5 µg per well engendered GFP that was visible 
under fluorescent microscopy (Fig. 1c,d, respectively). Treatment of human osteoblast-like MG-63 cells with 
25 ng/mL or 100 ng/mL rhVEGF165 protein for 24 hours resulted in a significant increase (116.4% and 116.0% 
respectively; P < 0.0001) in DNA content compared to non-treated controls as measured using the PicoGreen 
assay. In contrast, transfection with VEGF165 RNA had no significant effect on proliferation (Fig. 1e). Consistent 
with these observations, transfection of MG-63 cells with 1 µg per well of VEGF165 RNA significantly increased 
secretion of VEGF protein by 228% (MG-63GFP = 596 ± 69.5 pg/mL, MG-63VEGF165 = 1958 ± 142.2 pg/mL, 
P < 0.001 Fig. 1f).
Effect of VEGF165 RNA transfected MG-63 cells upon angiogenesis in the CAM assay. Following 
in vitro demonstration of modulation of VEGF production in human osteoblast-like MG-63 cells, angiogenesis 
was examined using VEGF165 RNA transfected MG-63 cells in the CAM assay. Angiogenesis was quantified from 
five regions within individual CAM membranes using the Chalkley assay (representative images in Fig. 2a). The 
Chalkley score for angiogenesis in CAM assays following culture with polycaprolactone (PCL) scaffolds seeded 
with MG-63 cells was 5.0 ± 1.50. In contrast, transfected
MG-63VEGF165 cells on PCL scaffolds placed on the CAM demonstrated significantly enhanced angiogenesis 
(Chalkley score 7.6 ± 1.96; P < 0.001). The addition of a single dose of 10 µL of rhVEGF165 (1 µg/mL) resulted in 
enhanced angiogenesis (Chalkley score 6.3 ± 1.39; P < 0.05, Fig. 2b) although this did not reach the same level as 
the MG-63VEGF165 group.
Direct delivery of rhVeGf165 protein increases bone volume. Following evidence of enhanced angi-
ogenesis in ovo, angiogenesis was examined using an in vivo murine calvarial model. Mice with calvariae treated 
with rhVEGF165 protein or transfected with GFP or VEGF165 RNA in vivo were scanned by µCT on the day of 
treatment, after 28 days and, after 42 days whereupon the experiments were stopped. Changes in bone formation 
(region of interest) were examined across the central area of the calvariae over the parietal bones and sagittal 
suture corresponding to the site of transfection (Fig. 3a). Changes in bone thickness were recorded over time 
and visualised using colour coded reconstructed images with relatively thinner bone identified in purple and, 
dense bone in green (Fig. 3b). Analysis by in vivo µCT revealed significant increases in calvarial bone volume in 
mice treated with GFP RNA (Fig. 3c, P < 0.01), VEGF165 RNA (Fig. 3d, P < 0.05) and rhVEGF165 protein (Fig. 3e, 
P < 0.01). Changes in bone volume varied across groups in the time frame of the study. GFP RNA transfected 
calvariae increased in volume by 18.51%, while mice transfected with VEGF165 RNA increased by 21.75% and 
mice treated with rhVEGF165 displayed a significant increase in bone volume of 23.31% (P < 0.05 cf GFP RNA 
transfected controls, Fig. 3f).
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Calvarial bone thickness increased from an average of 0.3122 ± 0.0151 mm on day 0 to 0.3845 ± 0.0112 mm 
on day 42 in rhVEGF165 treated animals (P < 0.05). There were no significant increases in calvarial bone thickness 
between 0 and 42 days in either the GFP RNA or the VEGF165 RNA treated mice (Fig. 3g). The mean increase in 
bone thickness between 0 and 42 days for rhVEGF165 treated animals was 0.0732 ± 0.0202 mm, significantly more 
than the value of 0.0442 ± 0.0132 mm observed in VEGF165 RNA treated mice (Fig. 3h).
transfection with VEGF165 RnA increases intraosseous vascular branching in vivo. Reconstructed 
images from high resolution XCT allowed visualisation of bone topography, intraosseous vascular space and vas-
cular branching (Fig. 4a). Calvarial thickness, bone volume and intraosseous space were mapped in 3-dimensions 
using Avizo software and the number of branching nodes quantified from a skeletonized map of the intraosseous 
vascular cavities.
Figure 1. Contrasting effects of rhVEGF165 RNA transfection and rhVEGF165 protein in vitro. MG-63 cells 
cultured in 24 well plates were transfected with either GFP or VEGF165 RNA, or treated with 25 ng/µl rhVEGF165. 
GFP fluorescence was visualised after 16–20 hours as a positive control for transfection (a–d). A titration of GFP 
RNA was used from 0.1 µg (a), 0.5 µg (b), 1 µg (c) to 5 µg per well (d). Double stranded DNA quantified using 
the PicoGreen assay was used as a marker for cell proliferation and demonstrated a 116% increase in response 
to rhVEGF165 treatment at both 25 ng/mL and 100 ng/mL (N = 12 in total with 4 wells per treatment group and 
3 independent replica plates) (b). VEGF quantified from conditioned media by ELISA was on average 596 pg/
mL from MG-63 GFP cells and 1958 pg/mL from MG-63 VEGF165 cells (c) (N = 3 per treatment group). Statistical 
analyses were carried out in IBM SPSS Statistics 25 with ANOVA and Tukey post-hoc tests or t-tests where 
comparing just two treatment groups (***P < 0.001, ****P < 0.0001).
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Calvarial thickness recorded from each region of interest (ROI) by XCT was 0.1760 ± 0.0079 mm from GFP 
RNA transfected mice and 0.2095 ± 0.0092 mm from rhVEGF165 treated mice (P < 0.05 cf GFP RNA transfec-
tion). Calvarial thickness measured by XCT from VEGF RNA transfected mice was 0.1975 ± 0.0197 mm (Fig. 4b).
The mean density of branching nodes, normalised to bone volume in each ROI, was 149.6 ± 41.5 per mm3 in 
calvariae from GFP RNA transfected mice and observed to be significantly increased in VEGF165 RNA transfected 
mice (230.1 ± 54.1 per mm3; P < 0.05 cf GFP RNA transfection). In contrast, within the calvariae of rhVEGF165 
treated mice the mean value was 192.6 ± 31.9 per mm3 and was not significantly different to the other treatment 
groups (Fig. 4c).
Discussion
The central aim of the present study was to examine the different effects of rhVEGF165 protein and transfected 
VEGF165 RNA upon angiogenesis and bone formation. The current study shows that rhVEGF165 protein pro-
duced, overall, an osteogenic effect with increased proliferation of human osteoblast-like MG-63 cells at 25 ng/mL 
and 100 ng/mL in vitro (Fig. 1e) corresponding to a previous study where matching concentrations of rhVEGF165 
decreased trabecular spacing, increased bone volume and trabecular number in organotypic cultures embryonic 
chick femurs30. Consistent with these in vitro findings, treatment with rhVEGF165 enhanced calvarial bone thick-
ness in vivo compared to other treatment groups (Figs. 3g,h and 4b). Differences in osteogenesis within calvariae 
were quantifiable within a longitudinal in vivo µCT study, which allowed direct comparison between bone thick-
ness and volume within individual mice at specific time points to counteract any variance in bone parameters 
within treatment groups (Fig. 3). Calvariae were further analyzed ex vivo by XCT to generate higher resolution 
scans over a smaller ROI compared to in vivo µCT. This technique demonstrated that calvariae from rhVEGF165 
treated mice were significantly thicker than GFP RNA controls (Fig. 4b)
Although dosages of between 12.5 and 50 ng/mL of rhVEGF165 have previously been shown to increase tubule 
formation from epithelial cells in vitro31, it was transfection with VEGF165 RNA which promoted, predominantly, 
angiogenesis with increased VEGF protein secretion in vitro (Fig. 1f) and an increase of angiogenesis in the CAM 
assay that was stronger than observed with rhVEGF165 protein (Fig. 2a,b). Direct transfection of VEGF165 RNA 
into calvarial bones in vivo was found to increase branching of the intraosseous vascular cavity, quantified via a 
novel approach using X-ray computed tomography (Fig. 4c).
Figure 2. Vessel density is increased by transfected MG-63 cells and rhVEGF165 in the CAM assay. CAM assays 
were initiated on chicken eggs 10 days after fertilisation. Electrospun PCL scaffolds seeded with MG-63GFP or 
MG-63VEGF165 cells were placed on the CAM and additional eggs were treated with rhVEGF165 (10 µL of 1 µg/mL 
solution). After 7 days, the CAM membranes were harvested for quantification of angiogenesis with a dissecting 
microscope under which differences in treatment group were clearly visible (A). Angiogenesis was quantified 
from 5 regions per CAM using a Chalkley graticule in the eyepiece of the dissecting microscope. Mean 
Chalkley scores for each treatment group were 5.0 for membranes with MG-63 seeded PCL scaffolds (N = 6), 
7.6 with MG-63VEGF165 seeded PCL scaffolds (N = 4), and 6.3 with rhVEGF165 treatment (N = 3). Statistical 
tests were carried out in IBM SPSS statistics 25 using univariate analysis and Tukey post-hoc tests (*P < 0.05, 
***P < 0.001).
5Scientific RepoRtS |         (2019) 9:17745  | https://doi.org/10.1038/s41598-019-53249-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Bone volume is increased following direct in vivo treatment with rhVEGF165. Murine calvariae were 
directly transfected with GFP or VEGF165 RNA or treated with rhVEGF165 protein in vivo in the region indicated 
(a). Calvariae were scanned by in vivo µCT on days 0, 28 and 42. Colour coded reconstructions show thinner 
bone in purple and thicker bone in green between treatment groups and across the time course (b). Changes in 
bone volume were recorded in the ROI in all treatment groups along the 42-day time course (c–e). rhVEGF165 
protein treated calvariae demonstrated the highest percentage increase in bone volume (f), significantly 
increased bone thickness (g) and the greatest increase in thickness (h) (N = 4–5 mice per treatment group). 
Statistical tests were carried out in GraphPad Prism with ANOVA and Dunn’s multiple comparison or Tukey 
post-hoc tests (*P < 0.05, **P < 0.01).
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The contrasting effects of rhVEGF165 protein and transfection with VEGF165 RNA can be better understood in 
the context of prior investigations into VEGF delivery. Previous studies have indicated that the precise delivery 
mechanism employed can alter the effects of VEGF on bone in vivo with some approaches increasing either oste-
ogenesis or angiogenesis with other approaches promoting both. Subcutaneous injection of rhVEGF165 within a 
matrigel scaffold to an in vivo mouse model enhanced angiogenesis concomitantly with new bone formation32, 
partially consistent with the present data on calvarial bone formation but not angiogenesis following in vivo 
delivery of rhVEGF165. VEGF carrying adenovirus has been used for direct in vivo localised injection to increases 
osteoblast number and osteoid volume33. In contrast, the in vivo delivery of VEGF165 plasmid freeze dried into 
Figure 4. Intraosseous vascular branching is increased by in vivo transfection with VEGF165 RNA. Isolated 
murine calvariae were scanned ex vivo by XCT and each ROI was analyzed in Avizo 9.3 to generate detailed 3D 
reconstructions of the calvariae, the intraosseous space and skeletonized models of the vascular connectivity 
(a). Calvarial thickness was quantified by XCT (b). The number of branching nodes was normalised to bone 
volume to reveal increased intraosseous vascular branching following in vivo transfection with VEGF165 RNA 
(c). Statistical tests were carried out in GraphPad Prism using ANOVA and Dunnett’s post-tests (*=< P0.05).
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deproteinized bone and implanted into rabbit femoral drill defect, only increased formation of new capillary ves-
sels with no reported changes in bone volume34. This latter study parallels our own findings, whereby transfection 
increased intraosseous angiogenesis (Fig. 4c). Interestingly, rhVEGF165 increased bone thickness in vivo without 
significantly increasing intraosseous angiogenesis, while transfection with VEGF165 RNA produced what appeared 
to be almost the reverse effect. Possible explanations may include differences in the relative abundance of VEGF 
receptors on bone cell populations required for angiogenesis versus osteogenesis. Interestingly, the expression 
pattern of VEGF receptors in response to VEGF protein has previously been shown to be higher in co-cultures 
of human umbilical vein endothelial cells and human foetal diaphyseal/epiphyseal foetal femur cells compared 
to expression following individual cell culture30. It cannot be excluded that the dose response to VEGF var-
ies according to cell type, with a continuous low-level release of VEGF following transfection potentially more 
advantageous to angiogenic cells while a large single dose of VEGF protein could trigger osteoblast activity. 
Furthermore, it is possible that different cell populations may be more resilient to transfection than others with 
the resultant VEGF effects that would accompany. The ease of access of protein and RNA may be confounding 
variables given differences in size, charge, shape and stability all of which could affect subsequent permeation and 
angiogenic or bone cell population interactions and responses. Resolving these differences will ultimately inform 
treatment strategies and this area requires further investigation.
The dosages of RNA and protein that engendered increases in vascularisation during the CAM assay were 
applied to murine calvariae in vivo, despite this, only VEGF RNA increased angiogenesis in the calvarial assay. It 
is of course plausible that a particular concentration of rhVEGF165 protein that has a pro-angiogenic effect in the 
CAM may not have the same effect in an in vivo calvarial model as our data show. An alternative could be to carry 
out dose responses in vivo and future studies could test additional concentrations. However, for the purposes of 
this study, and to try and address and meet the principles of the 3Rs (Replacement, Reduction and Refinement) 
it was decided not to carry out full dose responses in vivo which would have multiplied the numbers of animals 
required.
Quantification of vasculature within bone is a substantial challenge. Histological sections are typically too thin 
to enable the visualisation in three dimensions of the patterning of the bone vasculature. Generation of thicker 
sections and immunofluorescent labelling has enabled visualisation of bone vasculature in improved detail35 but 
even the evaluation of histological slices several hundred of micrometres thick cannot facilitate the quantitation 
of all of the vascular branching and connectivity existing within a sample. A superior approach would involve 
three-dimensional imaging to allow the visualisation, reconstruction and quantification of bone vasculature. 
However, µCT lacks the resolution and sensitivity required to achieve such an objective. Blood vessels have been 
previously visualised in cortical bone using high-resolution synchrotron-based computed tomography at the 
TOMCAT beamline of the Swiss Light Source36; however access to any synchrotron is often time limited and 
financially prohibitive in many cases. In this study, we have quantified the effects of different VEGF delivery 
methods, across treatment groups, using a ‘synchrotron like’ lab-based system that has enabled a novel use for 
X-Ray microscopy and quantification of the intraosseous vascular space to visualise and quantify bone vascular 
branching. The approach demonstrated that VEGF transfection in vivo could increase intraosseous branching 
that was quantifiable ex vivo. It is possible that porous structures found within calvariae by XCT could include 
spongey diploe; however, this would be unusual as the branching patterns observed are highly characteristic 
of vasculature. Future experiments could include the use of nanoparticle-based or heavy-metal-based contrast 
agents to highlight the soft tissue of the vasculature within calvariae. Importantly, this technique offers wide 
potential in applications such as quantification of blood vessels in other bone types in addition to calvariae or, 
angiogenesis, within calcified tumours such as osteosarcoma.
In conclusion, direct delivery of VEGF to bone promises a useful approach for the enhancement of angiogen-
esis and osteogenesis. However, the precise effect depends significantly on the delivery mechanism employed. 
A transient single dose of recombinant protein enhances expansion of bone formation while a steady release of 
VEGF, following transfection, promotes angiogenesis. Confirmation of the mechanisms at play and the optimal 
delivery approach auger well for improved bone health for an ageing population.
Methods
cell culture and transfection. For the preparation of RNA used in transfection, the full cDNA of human 
VEGF165A and EGFP was reverse translated and codon optimised for maximal human expression. This was de 
novo synthesised (Eurofins MWG) and cloned into a standard vector. mRNA DNA templates were generated by 
PCR. HiScribe T7 ARCA mRNA kits (NEB) were used to generate modified mRNAs containing 5mCTP and 
Pseudo-UTP. These also contained an anti-reverse cap anolg (ARCA) and a polyA tail according to the kit. The 
modified nucleotides have been shown to suppress RNA-mediated innate immune activation in vivo. DNase I and 
LiCl were employed for DNA template removal and rapid mRNA purification. Human osteoblast-like MG-63 
osteosarcoma were from ATCC and all cell culture reagents supplied by Thermo Fisher Scientific unless specified. 
MG-63 cultures were maintained in T75 flasks containing complete media of 10% FBS in DMEM with 100 U/
mL penicillin and 100 µg/mL streptomycin (under standard cell culture conditions at 37 °C, 5% CO2). Cells were 
passaged when cultures reached 70% confluence. For transfection, 40,000 cells were plated per well in complete 
media in a 24 well plate. After 24 hours, the complete media was removed and cultures were rinsed twice with 1x 
PBS before being replaced with 250 µl of OptiMEM per well. For each well a transfection solution was prepared in 
two stages. A solution of 1 µg either VEGF165 or GFP RNA and 25 µl OptiMEM was rested at room temperature for 
5 minutes while a solution of 0.75 µl of lipofectamine 2000 and 25 µl OptiMEM was prepared. Both solutions were 
combined and incubated at room temperature for 20 minutes to allow lipofectamine-RNA complexes to form 
and 50 µl of transfection solution was added to each well of a 24 well plate. Cells were incubated in transfection 
solution in OptiMEM for 5 hours. OptiMEM was used without FBS or antibiotics to enhance transfection effi-
ciency and minimise cell death, which can otherwise be exacerbated in combination with lipofectamine. Cultures 
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of transfected MG-63GFP and MG-63VEGF165 cells were rinsed with 1x PBS and returned to complete medium and 
GFP protein expression was checked after 16–20 hours with a Zeiss Axiovert 200 M inverted microscope as posi-
tive control for successful transfection at which point plates were then divided according to experiment.
MG-63 cells were seeded onto electrospun PCL scaffolds generously provided by J.Puetzer and M. Stevens 
(Imperial, UK). PCL discs cut using a 5 mm biopsy punch were sterilised in 70% ethanol and then under UV light. 
PCL discs were incubated with 20% BSA in 1x PBS for 1 hour to reduce hydrophobicity and enhance cell adhesion 
prior to cell seeding. To prevent floating, PCL discs were held down by insect pins positioned into a pre-prepared 
polydimethylsiloxane lining at the bottom of each well. MG-63 cells were plated at a density of 200,000 per PCL 
disc in 100ul complete media for each and incubated for one hour to allow cell attachment before topping up wells 
with media. For transfection, reagents were scaled up in proportion with cell number so that 5ug of RNA and 
3.75ul lipofectamine was used per PCL disc.
cell proliferation. The amount of DNA present was used as an indicator of differences in cell proliferation 
between treatment groups. Cells were lysed and freeze thawed 24 hours after transfection to release DNA which 
was quantified with the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific) according to the man-
ufacturer’s instructions.
RNA extractions, cDNA synthesis and quantitative PCR. RNA was extracted 24 hours after trans-
fection with the RNeasy plus minikit (Qiagen) following manufacturer’s instructions. RNA quantity and quality 
were evaluated with a Nanodrop Spectrophotometer (Labtech). cDNA synthesis was carried out with Superscript 
Vilo kit (Thermo Fisher Scientific). Gene expression was quantified by quantitative PCR. Each 25 µL reaction con-
tained 12.5 µl SYBR Green PCR Master Mix (Thermo Fisher Scientific), 250 nM of each primer, and 1ul cDNA. 
All reactions were carried out in triplicate on an AB7500 Real-Time PCR system (Applied Biosystems). Initial 
activation was at 95 °C for 10 minutes, followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 60 seconds. 
The 2-ΔΔCt method was used for the relative quantification of gene expression in MG-63VEGF165 cells com-
pared to MG-63GFP cells, and data were normalized to β-actin expression. Primer sequences used were VEGF 
forward CACACAGGATGGCTTGAAGA, VEGF reverse AGGGCAGAATCATCACGAAG, β-actin forward 
GGCATCCTCACCCTGAAGTA and β-actin reverse AGGTGTGGTGCCAGATTTTC.
VeGf eLiSA. MG-63GFP and MG-63VEGF165 cells in 24 well plates or on PCL scaffolds were rinsed three times 
with 1x PBS and incubated in serum free medium for 24 hours. Conditioned media samples were collected and 
quantified using the Human VEGF Quantikine ELISA Kit (RnD Systems, UK) according to the manufacturer’s 
instructions.
cAM assays. All egg chorioallantoic membrane (CAM) studies were undertaken following approval from 
the local Animal Welfare and Ethics Review Board (AWERB) University of Southampton and carried out in 
accordance with the guidelines and regulations stipulated in the Animals (Scientific Procedures) Act, UK 1986 
under the approved Home Office Project license (PPL 30/2762). CAM assays were performed based on previously 
established protocols37,38. Briefly, procedures began on eggs 10 days after fertilisation. Windows were made into 
the eggshell through which the CAM could be visualised. PCL scaffolds with either MG-63GFP cells, MG-63VEGF165 
cells or 10 µL of rhVEGF165 (1 µg/mL) were placed directly on to the CAM, windows were sealed with sterile 
parafilm and eggs incubated without rotation for a further 7 days. On day 17 CAM membranes were harvested 
and fixed in 4% PFA in 1x PBS. Angiogenesis in the CAM was quantified using a dissecting microscope with an 
eyepiece Chalkley graticule, which has been previously used to provide measurements of vascular density in the 
CAM assay39.
VeGf delivery in vivo. All mouse in vivo studies were undertaken following approval from the local Animal 
Welfare and Ethics Review Board (AWERB) University of Southampton and carried out in accordance with the 
guidelines and regulations stipulated in the Animals (Scientific Procedures) Act, UK 1986 under the approved 
Home Office Project license (PPL 30/2880).
A transfection solution containing 5 µg of GFP or VEGF165 RNA and 3.75 µl lipofectamine MessengerMAX 
made up to 10 µL total volume in 1x PBS was prepared 20 minutes prior to each procedure to provide an optimal 
time for RNA-lipofectamine complexes to form. Control solutions were made with rhVEGF165 (1 µg/mL) in 1x 
PBS. Age-matched wild type MF-1 mice were anaesthetised with fentanyl-fluanisone (Hypnorm; Janssen-Cilag 
Ltd.) and midazolam (Hypnovel; Roche Ltd.) in sterile water at a ratio of 1:1 and a dose of 10mL kg-1 intraperi-
toneally. A lengthways incision was made along the skull so that skin could be pulled back to expose the calvariae 
and any remaining soft tissues were scraped away. Solutions containing either RNA-lipofectamine complexes or 
rhVEGF165 protein were directly pipetted onto the exposed calvariae prior to suturing. Mice were incubated at 
37 °C on heat mats for recovery before being returned to cages provided with mouse chow and water ad libitum.
In vivo µct. Scans were performed on a Skyscan 1176 in-vivo CT scanner (Bruker) at 65 kV, 385 µA with a 
1 mm thick Aluminium filter. Exposure time was 135 ms with a 0.5°rotation step to achieve an 18 µm voxel size. 
Tomograms were reconstructed using NRecon (version 1.7.1.6, Bruker). The scan at the time of surgery was 
set as reference and each subsequent acquisition was 3D registered for perfect alignment to the reference using 
Dataviewer (version 1.5.1.2, Bruker). Datasets were analysed in CTAn (version 1.16.4.1, Bruker). The defined ROI 
was used in subsequent scans to determine bone development at the calvarial site. As greyscale of 200 or more 
corresponds to bone over 1 g/cm3 bone mineral density, high density bone volume was calculated using greyscale 
values 200–255.
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X-ray micro computed tomography and analysis. Mice were culled on day 42 and isolated calvar-
iae subsequently fixed in 4% paraformaldehyde for 48 hours and transferred to 70% ethanol prior to scanning. 
Isolated calvariae were imaged using high-resolution X-ray computed tomography (XCT) (ZEISS Xradia 520 
Versa, Carl Zeiss X-ray Microscopy, Pleasanton, CA, USA) set to operate at 60 kV, 5 W and an LE1 filter posi-
tioned directly after the X-ray source. X-ray projection images (2001 images) were collected over 360°at equal 
intervals with an isotropic voxel size of 3.15 µm (exposure time per projection was 6 seconds). Projections were 
then reconstructed using the manufacturer’s integrated software (Scout and Scan Reconstructor, Carl Zeiss X-ray 
Microscopy, Pleasanton, CA, USA), which utilises a filtered back projection reconstruction algorithm. The recon-
structed tomograms, 16-bit grey-level images, were analysed double blinded using Avizo 9.3 (Thermo Fisher 
Scientific) for image segmentation and quantification. Calvarial vasculature was segmented from surrounding 
bone by isolating the bone into a binary image using the Interactive Thresholding tool. The grey-level range for 
thresholding was manually determined for each sample and selected to ensure that the entire bone was included 
within the initial segmentation. The binary image of the bone was applied back to the full image volume and used 
to mask the bone area for an Interactive Thresholding to segment the bone vasculature. The binary image of the 
vasculature was used for quantitative analysis by implementing the Volume3d measurement tool. Only the vas-
culature that was fully contained within the bone was considered for analysis. The vasculature network and con-
nectivity were constructed using the Auto-Skeleton tool contained within the software. The number of branching 
nodes (3 of more branches) was normalised to bone volume within the ROI.
Statistics. Statistics were carried out using GraphPad Prism 8 with additional analysis in IBM SPSS Statistics 
25. Normality tests were carried out in GraphPad Prism 8. In analysis comprising two groups for comparison, 
significance was determined using a t-test. Where more than two groups were compared, significance was deter-
mined using ANOVA with appropriate post-hoc tests. Univariate Analysis of Variance and differences between 
individual treatment groups determined using Tukey post-hoc tests in IBM SPSS Statistics 25. Figures were gen-
erated in GraphPad Prism 8 and data presented with individual data points and mean with standard deviation 
error bars.
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